DGAP-News: myoscience to Present at the Piper Jaffray 25th Annual Health Care Conference

 | Source: EQS Group AG EQS Group AG 

myoscience 

21.11.2013 13:00
---------------------------------------------------------------------------

REDWOOD CITY, Calif., 2013-11-21 13:00 CET (GLOBE NEWSWIRE) --
California based myoscience, inc., developers of the iovera*(r) system powered
by 
Focused Cold Therapy(TM) for the treatment of peripheral nerve conditions,
announced today that it will be participating in the Piper Jaffray 25th Annual
Health Care Conference in New York. Clint Carnell, Chairman and Chief Executive
Officer, will discuss myoscience's platform technology using the
well-established science of cryoneuromodulation to precisely deliver cold for
use in pain management and other peripheral nerve conditions. Mr. Carnell is
scheduled to present on December 4, 2013 at 1:30 am ET. 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy, the
standard of care for the treatment of peripheral nerve conditions. Focused Cold
Therapy is the patented technology delivered by the iovera* system. The iovera*
system is currently approved in Europe and Canada for temporary wrinkle
reduction, temporary pain reduction and treatment of dermatologic conditions,
and is indicated in the United States for use in pain management and general
surgical use. For more information, please visit www.myoscience.com. 

(c) 2013 myoscience. All rights reserved. iovera* and Focused Cold Therapy are
trademarks of myoscience. 


         MEDIA RELATIONS
         Peter Osborne / posborne@myoscience.com
News Source: NASDAQ OMX



21.11.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      myoscience
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US9902131674
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------
GlobeNewswire